Yi Li1, Ying Chen1, Ling Tan1, Jing-Ying Pan1, Wei-Wei Lin1, Jian Wu1, Wen Hu2, Xue Chen1,3, Xiao-Dong Wang1,2. 1. Department of Histology and Embryology, Medical College, Nantong University, Nantong, China. 2. Key Laboratory for Neuroregeneration of Ministry of Education and Co-innovation Center for Neuroregeneration of Jiangsu Province, Nantong University, Nantong, China. 3. Wuxi Medical College, Jiangnan University, Wuxi, China.
Abstract
AIMS: Astroglial-fibrotic scar formation following central nervous system injury can help repair blood-brain barrier and seal the lesion, whereas it also represents a strong barrier for axonal regeneration. Intensive preclinical efforts have been made to eliminate/reduce the inhibitory part and, in the meantime, preserve the beneficial role of astroglial-fibrotic scar. METHODS: In this study, we established an in vitro system, in which coculture of astrocytes and meningeal fibroblasts was treated with exogenous transforming growth factor-β1 (TGF-β1) to form astroglial-fibrotic scar-like cell clusters, and thereby evaluated the efficacy of RNAi targeting ephrin-B2 in preventing scar formation from the very beginning. We further tested the effect of RNAi-based mitigation of astroglial-fibrotic scar on spinal axon outgrowth on a custom-made microfluidic platform. RESULTS: We found that siRNA targeting ephrin-B2 significantly reduced both the number and the diameter of cell clusters induced by TGF-β1 and diminished the expression of aggrecan and versican in the coculture, and allowed for significantly longer extension of outgrowing spinal cord axons into astroglial-fibrotic scar as assessed on the microfluidic platform. CONCLUSIONS: These results suggest that astroglial-fibrotic scar formation and particularly the expression of aggrecan and versican could be mitigated by ephrin-B2 specific siRNA, thus improving the microenvironment for spinal axon regeneration.
AIMS: Astroglial-fibrotic scar formation following central nervous system injury can help repair blood-brain barrier and seal the lesion, whereas it also represents a strong barrier for axonal regeneration. Intensive preclinical efforts have been made to eliminate/reduce the inhibitory part and, in the meantime, preserve the beneficial role of astroglial-fibrotic scar. METHODS: In this study, we established an in vitro system, in which coculture of astrocytes and meningeal fibroblasts was treated with exogenous transforming growth factor-β1 (TGF-β1) to form astroglial-fibrotic scar-like cell clusters, and thereby evaluated the efficacy of RNAi targeting ephrin-B2 in preventing scar formation from the very beginning. We further tested the effect of RNAi-based mitigation of astroglial-fibrotic scar on spinal axon outgrowth on a custom-made microfluidic platform. RESULTS: We found that siRNA targeting ephrin-B2 significantly reduced both the number and the diameter of cell clusters induced by TGF-β1 and diminished the expression of aggrecan and versican in the coculture, and allowed for significantly longer extension of outgrowing spinal cord axons into astroglial-fibrotic scar as assessed on the microfluidic platform. CONCLUSIONS: These results suggest that astroglial-fibrotic scar formation and particularly the expression of aggrecan and versican could be mitigated by ephrin-B2 specific siRNA, thus improving the microenvironment for spinal axon regeneration.
Authors: Jez Fabes; Patrick Anderson; Rafael J Yáñez-Muñoz; Adrian Thrasher; Caroline Brennan; Stephen Bolsover Journal: Eur J Neurosci Date: 2006-04 Impact factor: 3.386
Authors: Elizabeth J Bradbury; Lawrence D F Moon; Reena J Popat; Von R King; Gavin S Bennett; Preena N Patel; James W Fawcett; Stephen B McMahon Journal: Nature Date: 2002-04-11 Impact factor: 49.962
Authors: Maurizio Gulino; Donghoon Kim; Salvador Pané; Sofia Duque Santos; Ana Paula Pêgo Journal: Front Neurosci Date: 2019-07-05 Impact factor: 4.677